Plasminogen activators-Pipeline Insight, 2021 | Analytical Research Cognizance

Plasminogen activators-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667926
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Plasminogen activators - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Plasminogen activators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Plasminogen activators Understanding
Plasminogen activators: Overview
Plasmin is the serine protease responsible for degradation of fibrin. Two forms of the zymogen precursor plasminogen circulate in plasma, the native more abundant form, Glu-plasminogen, and the intermediate form Lys-plasminogen, formed by cleavage of the N-terminal peptide from Glu-plasminogen. The plasminogen activator (PA) system is an extracellular proteolytic enzyme system associated with various physiological and pathophysiological processes. The first-generation plasminogen activators like streptokinase and urokinase are compounds found in nature that lack fibrin selectivity, while second-generation activators including t-PA and scu-PA are natural human proteins that possess some fibrin selectivity and can be produced either by selected human cell cultures or by recombinant DNA methods. The third-generation plasminogen activators are numerous compounds that are in clinical development and possess enhanced properties as a result either of chemical modification or of the application of recombinant DNA technology.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Plasminogen activators R&D. The therapies under development are focused on novel approaches for Plasminogen activators.
Plasminogen activators Emerging Drugs Chapters
This segment of the Plasminogen activators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Plasminogen activators Emerging Drugs
TMS-007: TMS
TMS-007 is a plasminogen activator based small molecule that is associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis. TMS-007 is designed to restore blood flow following acute stroke. TMS-007 is currently being evaluated in a Phase 2 study in Japan, in patients with acute ischemic stroke (AIS).

Recombinant staphylokinase: Supergene
Recombinant staphylokinase is a Plasminogen activators containing Forteplase as the active substance. It is single chain molecule that consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism and stroke.
Further product details are provided in the report……..

Plasminogen activators: Therapeutic Assessment
This segment of the report provides insights about the different Plasminogen activators drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Plasminogen activators
There are approx. 10+ key companies which are developing the Plasminogen activators. The companies which have their Plasminogen activators drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III and
Mid-stage products (Phase II and
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Plasminogen activators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Plasminogen activators: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Plasminogen activators therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Plasminogen activators drugs.

Plasminogen activators Report Insights
Plasminogen activators Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Plasminogen activators Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Scenario and Emerging Therapies:
How many companies are developing Plasminogen activators drugs?
How many Plasminogen activators drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for Plasminogen activators?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Plasminogen activators therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Plasminogen activators and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Genentech
TMS
Tasly Pharmaceutical
Cereno Scientific
Supergene
Boehringer Ingelheim
Chiesi Farmaceutici

Key Products
Tenecteplase
TMS 007
Prourokinase recombinant
CS-1
Recombinant staphylokinase
Alteplase
CUSA-081

Introduction
Executive Summary
Plasminogen activators: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Plasminogen activators – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Plasminogen activators companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Plasminogen activators Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TMS 007: TMS
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CS-1: Cereno Scientific
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Plasminogen activators Key Companies
Plasminogen activators Key Products
Plasminogen activators- Unmet Needs
Plasminogen activators- Market Drivers and Barriers
Plasminogen activators- Future Perspectives and Conclusion
Plasminogen activators Analyst Views
Plasminogen activators Key Companies
Appendix

Table 1 Total Products for Plasminogen activators
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Plasminogen activators
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products